AstraZeneca to collaborate with Innate Pharma on commercialisation for IPH2201in immuno-oncology
Friday, April 24, 2015
AstraZeneca to collaborate with Innate Pharma on commercialisation of IPH2201in immuno-oncology
AstraZeneca and Innate Pharma announce co-development and commercialisation collaboration for IPH2201
AstraZeneca and MedImmune have entered into a collaboration to accelerate and broaden development of Innate Pharma SA's proprietary anti-NKG2A antibody, IPH2201
AstraZeneca will make an initial payment to Innate of $250 million
AstraZeneca will pay a further $100 million prior to initiation of phase III development
Arrangement includes right for Innate to co-promote in Europe for a 50% profit share in territory
Transaction is expected to become effective in Q2 of 2015
reuters.com
